Study guide

12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

Key Takeaways Explain This Topic AI

Oral bisphosphonates inhibit osteoclast farnesyl pyrophosphate synthase and must be taken fasting with a full glass of water while staying upright for 30 minutes; rare adverse effects are osteonecrosis of the jaw and atypical femoral fractures.

Denosumab is a RANKL antibody given every 6 months; stopping it without a follow-on agent causes rebound vertebral fractures, and it carries a boxed warning for severe hypocalcemia in advanced CKD.

Estrogen-containing hormone therapy and raloxifene increase venous thromboembolism risk, which compounds the risk from foot surgery and immobilization.

First-generation H1 antihistamines such as diphenhydramine are sedating and anticholinergic and are best avoided in older adults; second-generation agents such as cetirizine, loratadine and fexofenadine are minimally sedating.

Becaplermin (recombinant PDGF-BB) gel is FDA-approved for diabetic neuropathic foot ulcers with adequate blood supply; supplements are not FDA-approved for efficacy, and St. John's wort, ginkgo, fish oil and red yeast rice cause clinically important interactions.

Last updated: October 2026

12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

The outline groups other pharmaceutical agents (hormone therapy, bisphosphonates, antihistamines and growth factors) and complementary and alternative agents (cannabinoids, vitamins, supplements and herbal products). Bone-active drugs matter for fracture and fusion healing, growth factors are used in diabetic wound care, and many patients take supplements without mentioning them.

Hormone Therapy

Agent Indications Key risks and interactions

Estrogen with or without progestin (menopausal hormone therapy) Vasomotor symptoms, prevention of genitourinary atrophy Venous thromboembolism , stroke; with a progestin, breast cancer risk; unopposed estrogen raises endometrial cancer risk

Combined oral contraceptives Contraception VTE risk , which adds to the risk from lower extremity surgery, casting and immobilization; risk is higher in smokers older than 35

  • Raloxifene (SERM) Osteoporosis, breast cancer risk reduction VTE , hot flashes, leg cramps
  • Tamoxifen (SERM) Breast cancer VTE, endometrial cancer

Levothyroxine Hypothyroidism Narrow therapeutic range; take on an empty stomach and separate from calcium, iron and PPIs; overtreatment causes atrial fibrillation and bone loss

  • Testosterone Hypogonadism Erythrocytosis, possible VTE, acne
  • Glucocorticoids Anti-inflammatory and replacement Covered in 11.3 and 12.4
  • Bone-Active Agents

Drug Mechanism Key points

Oral bisphosphonates (alendronate, risedronate) Bind hydroxyapatite; nitrogen-containing agents inhibit farnesyl pyrophosphate synthase in osteoclasts, causing loss of function and apoptosis Take fasting with a full glass of plain water and remain upright for 30 minutes (pill esophagitis); avoid with severe CKD; rare osteonecrosis of the jaw and atypical femoral fractures ; a drug holiday is considered after about 3–5 years in lower-risk patients

Zoledronic acid (IV) Same class, given yearly Acute-phase flu-like reaction; renal monitoring

Denosumab Monoclonal antibody to RANKL , given every 6 months Rebound multiple vertebral fractures if stopped without a follow-on agent; boxed warning for severe hypocalcemia in advanced CKD

Teriparatide, abaloparatide PTH or PTHrP analogs given intermittently, which are anabolic Hypercalcemia, orthostasis; given daily by injection

Romosozumab Antibody to sclerostin , which increases bone formation and reduces resorption Boxed warning for MI, stroke and cardiovascular death

Calcitonin Inhibits osteoclasts Weak antifracture effect; nasal formulation

Podiatric relevance. Low bone density, vitamin D deficiency and anti-resorptive history are considered when planning arthrodesis or managing stress fractures. Charcot neuroarthropathy is managed with offloading and immobilization. Trials of bisphosphonates in active Charcot foot have not shown clinically meaningful benefit, and current diabetic foot guidance does not recommend them routinely.

Antihistamines

Class Examples Features

First-generation H1 antagonists Diphenhydramine, hydroxyzine, chlorpheniramine, promethazine Cross the blood-brain barrier: sedation, anticholinergic effects (urinary retention, confusion); on lists of drugs to avoid in older adults

Second-generation H1 antagonists Cetirizine, loratadine, fexofenadine Minimal sedation; first choice for urticaria and allergic rhinitis

H2 antagonists Famotidine Acid suppression (12.3); sometimes added for urticaria and infusion reactions

Antihistamines treat urticaria, pruritus and vancomycin infusion (flushing) reactions (11.1). They are adjuncts, not substitutes, for epinephrine in anaphylaxis .

Growth Factors

Becaplermin gel (recombinant human PDGF-BB ) is FDA-approved for lower extremity diabetic neuropathic ulcers that extend into subcutaneous tissue or deeper and have an adequate blood supply . It is used alongside debridement, offloading and infection control. Its earlier boxed warning about cancer mortality was removed from the label in 2018.

Hematopoietic growth factors: filgrastim and pegfilgrastim (G-CSF) shorten chemotherapy-induced neutropenia and cause bone pain. Erythropoiesis-stimulating agents (epoetin alfa, darbepoetin) treat anemia of CKD and chemotherapy but carry boxed warnings for thrombosis, stroke and mortality when hemoglobin is pushed too high. Thrombopoietin receptor agonists (romiplostim, eltrombopag) treat immune thrombocytopenia.

Routine G-CSF is not recommended for treating diabetic foot infection.

Complementary and Alternative Agents

Under the Dietary Supplement Health and Education Act (1994) , supplements do not need FDA approval for efficacy before marketing. Product content and purity vary, so always ask about them during medication reconciliation.

Agent Proposed use Clinically important risks

Cannabinoids: THC (CB1 agonist), CBD (non-intoxicating) Pain, nausea, seizures Sedation, cognitive and psychiatric effects; CBD inhibits CYP2C19 and CYP3A4 (raises clobazam and warfarin effect) and can raise liver enzymes. Prescription products include dronabinol and nabilone (chemotherapy nausea, appetite) and purified CBD for specific seizure disorders. Legal status differs between federal and state law

Vitamins in high doses General health Vitamin A: teratogenic and hepatotoxic. Vitamin B6: sensory neuropathy with chronic high intake. Vitamin D: hypercalcemia. Niacin: flushing and hepatotoxicity. Vitamin E: bleeding. Vitamin K: lowers warfarin effect

St. John's wort Depression CYP3A4 and P-glycoprotein induction ; serotonin syndrome

Ginkgo, garlic, ginger, fish oil Circulation, cardiovascular health Antiplatelet effects with bleeding risk ; many surgeons ask patients to stop them before surgery

Glucosamine and chondroitin Osteoarthritis Inconsistent benefit; possible INR increase with warfarin

Red yeast rice Cholesterol Contains monacolin K, chemically identical to lovastatin : myopathy and CYP3A4 interactions

  • Licorice (glycyrrhizin) Digestive complaints Pseudohyperaldosteronism: hypertension, hypokalemia , edema
  • Kava Anxiety Hepatotoxicity
  • Ephedra (ma huang) Weight loss FDA ban (2004) after strokes, MIs and arrhythmias

Important

A supplement history is part of a complete medication history. Bleeding after surgery, an unstable INR, unexplained hypokalemia or statin-like myopathy can all trace back to products patients regard as "natural."